Phillip G. Febbo, MD

Dartmouth College, Hanover, NH, BA, 1984-1988, Biology
University of California, San Francisco, CA, 1990-1991, Pathology
University of California, San Francisco, CA, MD, 1988-1993, Medical School
Brigham and Womens Hospital, Boston, MA, Residency, 1993-1996, Internal Medicine
Dana Farber Cancer Institute, Boston, MA, Fellowship, 1996-1999, Oncology

• 1993-2004
  Clinical Instructor in Medicine, Harvard Medical School, Boston, MA
• 1996-2004
  Associate Physician, Brigham and Women's Hospital, Boston, MA
• 1999-2004
  Instructor in Medicine, Dana Farber Cancer Institute, Boston, MA
• 1999-2004
  Post-doctoral Fellow, Dana Farber Cancer Institute, Boston, MA
• 1999-2004
  Visiting Scholar, Whitehead Institute Center for Genomic Research, MIT, Cambridge, MA
• 2004-2008
  Assistant Professor, Department of Medicine, Duke University Medical Center, Durham, NC
• 2004-2008
  Assistant Professor, Department of Molecular Genetics and Microbiology, Duke University, Durham, NC
• 2005-2010
  Associate Member, Duke Comprehensive Cancer Center, Durham, NC
• 2008-2010
  Associate Professor, Department of Medicine, Duke University Medical Center, Durham, NC
• 2008-2010
  Associate Professor, Department of Molecular Genetics and Microbiology, Duke University, Durham, NC
• 2010-present
  Associate Professor in Residence, Department of Medicine, University of California San Francisco, San Francisco, CA

• 1997
  National Cancer Institute Oncology Fellowship, Dana Farber Cancer Institute, Boston MA
• 1998
  Friends of Dana Farber Oncology Fellowship, Dana Farber Cancer Institute, Boston MA
• 1998
  AACR meeting Travel Award, New research approaches in the Prevention and Cure of Prostate Cancer
• 1999
  American Society of Clinical Oncology, Young Investigator Award
• 2000
  Hershey Family Foundation, Young Investigator Award, Beth-Israel Deaconess Hospital
• 2001
  CapCURE, Young Investigator Award
• 2003
  Prostate Cancer Foundation Award
• 2004
  Prostate Cancer Foundation Award
• 2005
  Damon Runyon Cancer Research Foundation Clinical Investigator Award
• 2005
  Department of Defense, New Investigator Award
• 2006
  Department of Defense, Physician Research Training Award
• 2006
  Department of Defense, Idea Development Award
• 2009
  Elected to American Society of Clinical Investigation

• Febbo PG, Kantof PW, Platz EA, Casey D, Batter S, Giovannucci E, Hennekens C, Stampfer M. The V89L Polymorphism in the 5 alpha-reductase Type 2 Gene and Risk of Prostate Cancer. Cancer Research (1999); 59(23): 5878-81
• Singh D*, Febbo PG*, , Ross K, Jackson DG, Manola J, Ladd C, Tamayo P, Renshaw AA, D’Amico AV, Richie JP, Lander ES, Loda M, Kantoff PW, Golub TR, Sellers WR. Gene expression correlates of clinical prostate cancer behavior. Cancer Cell(2002); 1(2): 203-209 (*Drs. Singh and Febbo contributed equally to this paper)
• Lieberfarb ME, Lin M, Lechpammer M, Li C, Tanenbaum DM, Febbo PG,Wright R, Shim J, Kantoff PW, Loda M, Meyerson M, Sellers WR. Genome-wide loss of heterozygosity analysis from laser capture microdissected prostate cancer using single nucleotide polymorphic allele arrays and a novel bioinformatics platform dChipSNP. Cancer Research (2003) 63(16): 4781-5
• Paris PL, Andaya A, Fridlyand J, Jain AN, Weinberg V, Kowbel D, Brebner JH, Simko J, Watson JE, Volik S, Albertson DG, Pinkel D, Alers JC, van der Kwast TH, Vissers KJ, Schroder FH, Wildhagen MF, Febbo PG, Chinnaiyan AM, Pienta KJ, Carroll PR, Rubin MA, Collins C, van Dekken H. Whole genome scanning indentifies genotypes associated with recurrence and metastasis in prostate tumors. Hum Mol Genet. (2004) 13(13):1303-13
• Alvarez J, Febbo PG, Ramaswamy S, Loda M, Richardson A, Frank DA. Identification of a genetic signature of activated STAT3 in human tumors. Cancer Res. (2005) 65(12):5054-62.
• Febbo PG, Richie JP, George DJ, Loda M, Manola J, Shankar S, Barnes AS, Tempany C, Catalona W, Kantoff PW, Oh WK. Neoadjuvant docetaxel prior to radical prostatectomy in patients with high risk localized prostate cancer. (In press, Clin Cancer Res. (2005); 11(14):5233-40.
• Febbo PG, Thorner A, Rubin MA, Loda M, Kantoff PW, Oh WK, Golub TR, George D. The application of oligonucleotide microarrays to assess the biological effects of neoadjuvant imatinib mesylate treatment for localized prostate cancer. Clin Cancer Res (2006); 12(1): 152-8.
• Bismar TA, Demichelis F, Riva A, Kim R, Varambally S, He L, Kutok J, Aster JC, Tang J, Kuefer R, Hofer MD, Febbo PG, Chinnaiyan A, Rubin MA. Defining aggressive prostate cancer using a 12-gene model. Neoplasia (2006); 8(1):59-68. PMCID: PMC1584291
• Edelman E, Porello A, Balakumaran B, Bild A, Febbo PG, Mukherjee S. Analysis of sample set enrichment scores: assaying the enrichment of sets of genes for individual samples in genome-wide expression profiles. Bioinformatics (2006); 22(14): e108-16.
• Hsu D, Balakumaran B, Acharya CR, Vlahovic V, Walters KS, Garmen K, Anders C, Riedel RF, Lancaster J, Harpole D, Dressman HK, Nevins JR, Febbo PG, Potti A. Pharmocogenomic Strategies Provide a Rational Approach to the Treatment of Cisplatin-resistant Patients. JCO (2007); 25(28): 4350-7.
• Febbo PG*, Mulligan MG, Slonina DA, Stegmaier K, Di Vizio D, Martinez PR, Loda M, Taylor SC. Literature lab: a method of automated literature interrogation to infer biology from microarray analysis. BMC Genomics (2007); 8:461. PMCID: PMC2244637 *Corresponding Author
• Mendiratta P and Febbo PG. Genomic Signatures Associated with the Development, Progression, and Outcome of Prostate Cancer. Mol. Diag. & Therapy (2007); 11(6): 345-354
• Edelman E, Guinney J, Chi JT, Febbo PG*, Mukerjee S*. Modeling cancer progression via pathway dependencies. PLOS Computational Biology (2008); 4(2):e28. PMCID: PMC2242820*Contributed Equally as Senior Author
• Mendiratta P, Mostghel E, Guinney J, Tewari AK, Porrello A, Barry WT, Nelson P, Febbo PG. A genomic strategy for targeting therapy in castration-resistant prostate cancer. JCO (2009); 27(12): 2022-9.
• Chang JT, Carvalho C, Mori S, Bild AH, Gatza ML, Wang Q, Lucas JE, Potti A, Febbo PG, West M, Nevins JR. A genomic strategy to elucidate modules of oncogenic pathway signaling networks. Mol Cell (2009); 34(1): 104-14.